Improved survival with combination oxaliplatin, irinotecan, cetuximab for metastatic pancreatic cancer

被引：0
|
作者：
Lee, F. [1 ]
Roach, M. [1 ]
Duong, L. [1 ]
Heywood, G. [1 ]
Parasher, G. [1 ]
Rasila, K. [1 ]
机构：
[1] Univ New Mexico, Albuquerque, NM 87131 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15180
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase two clinical trial of combination oxaliplatin, irinotecan, and cetuximab for patients with locally advanced or metastatic pancreatic cancer.
    Abdou, Yara
    Friend, Sarah Cooke
    Patt, Yehuda Z.
    Gan, Christine
    Lee, Fa-Chyi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer
    Larsen, Finn Ole
    Pfeiffer, Per
    Nielsen, Dorte
    Skougaard, Kristin
    Qvortrup, Camilla
    Vistisen, Kirsten
    Fromm, Anne-Lene
    Jorgensen, Trine L.
    Bjerregaard, Jon K.
    Hoegdall, Estrid
    Jensen, Benny V.
    ACTA ONCOLOGICA, 2011, 50 (04) : 574 - 577
  • [3] COMBINATION CHEMOTHERAPY WITH BIWEEKLY CETUXIMAB AND IRINOTECAN FOR WILD-TYPE KRAS METASTATIC COLORECTAL CANCER, REFRACTORY TO BOTH OXALIPLATIN AND IRINOTECAN
    Barbosa, Caroline
    Sousa, Romulado
    Sabbaga, Jorge
    Cotti, Guilherme
    Saragiotto, Daniel
    Hoff, Paulo
    ANNALS OF ONCOLOGY, 2011, 22 : v103 - v103
  • [4] OXALIPLATIN VERSUS IRINOTECAN IN COMBINATION TO CETUXIMAB FOR METASTATIC COLORECTAL CANCER. A SYSTEMATIC REVIEW WITH META-ANALYSIS
    Sasse, Andre Deeke
    Conceicao, Vinicius Correa
    ANNALS OF ONCOLOGY, 2011, 22 : v100 - v100
  • [5] Cetuximab and irinotecan in patients with colorectal cancer refractory to oxaliplatin and irinotecan
    Gonzalez-Baron, M.
    Blanco, M.
    Feliu, J.
    Gomez, C.
    Casado, E.
    Castro, J.
    Belda-Iniesta, C.
    Garrido, M.
    Aguayo, C.
    Campos, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer
    Braghiroli, Maria Ignez Freitas Melro
    Filho, Daniel Santos Rocha Sobral
    Fagundes, Juliana Goes Martins
    Mendoza, Elizabeth Zambrano
    Neffa, Maria Fernanda Batistuzzo Vicentini
    Campos, Karla Souza
    da Fonseca, Leonardo Gomes
    Bonadio, Renata Colombo
    Talans, Aley
    Braghiroli, Oddone Freitas Melro
    Mathias-Machado, Maria Cecilia
    Sabbaga, Jorge
    Venchiarutti, Camila Motta
    Hoff, Paulo Marcelo Gehm
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 42
  • [7] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Kohei Shitara
    Satoshi Yuki
    Motoki Yoshida
    Daisuke Takahari
    Setsuo Utsunomiya
    Tomoya Yokota
    Yozo Sato
    Yoshitaka Inaba
    Masahiro Tajika
    Hiroki Kawai
    Hidekazu Yamaura
    Mina Kato
    Kentaro Yamazaki
    Yoshito Komatsu
    Kei Muro
    Investigational New Drugs, 2012, 30 : 787 - 793
  • [8] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Shitara, Kohei
    Yuki, Satoshi
    Yoshida, Motoki
    Takahari, Daisuke
    Utsunomiya, Setsuo
    Yokota, Tomoya
    Sato, Yozo
    Inaba, Yoshitaka
    Tajika, Masahiro
    Kawai, Hiroki
    Yamaura, Hidekazu
    Kato, Mina
    Yamazaki, Kentaro
    Komatsu, Yoshito
    Muro, Kei
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 787 - 793
  • [9] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Yuki, S.
    Shitara, K.
    Yoshida, M.
    Takahari, D.
    Utsunomiya, S.
    Yokota, T.
    Sato, Y.
    Tajika, M.
    Muro, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [10] PHASE II STUDY OF COMBINATION CHEMOTHERAPY WITH BIWEEKLY CETUXIMAB AND IRINOTECAN FOR WILD-TYPE KRAS METASTATIC COLORECTAL CANCER REFRACTORY TO IRINOTECAN, OXALIPLATIN, AND FLUOROPYRIMIDINES
    Yuki, S.
    Shitara, K.
    Yoshida, M.
    Takahari, D.
    Utsunomiya, S.
    Yokota, T.
    Sato, Y.
    Tajika, M.
    Muro, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 216 - 216
12345